Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy. Symbiosis provides niche, sterile manufacturing services to global biotechnology and pharmaceutical company clients that are developing novel drug therapies and vaccines for use in clinical trials or the commercial market. Symbiosis’s facility at Stirling Innovation Park was purpose built in 2011 to manufacture deliberately small...
Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials. Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply. The agreement follows AstraZeneca’s recent announcement...
A new research centre to develop and manufacture medical devices in Scotland has been launched. The Medical Device Manufacturing Centre (MDMC) will provide expert advice to small and medium sized companies to support them in the advancement and production of medical devices that are crucial for the clinical care of patients. The MDMC is being launched thanks to £3.7 million funding from the Advancing Manufacturing...
Up to 150 researchers from the Centre for Inflammation Research are being re-deployed to work on a project that aims to test existing and experimental drugs to find a treatment for Covid-19. The team believe new therapies could be discovered and implemented before a vaccine becomes widely available by repurposing medicines for other conditions that are already in clinical use or are currently being tested....
NovaBiotics, the clinical stage antimicrobials drug discovery company, announces the rapid repurposing of Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections. Nylexa ‘supercharges’ antibiotics, boosting their efficacy against difficult to treat and even drug resistant bacteria. The active ingredient of Nylexa is already in advanced clinical trials. It has proven to be safe and effective in clinical studies carried out across the...
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing announces that it has signed a Memorandum of Understanding (“MOU”) with three other companies from across the UK, in conjunction with the University of Oxford to form the UK Rapid Test Consortium (“UK-RTC”) in order to jointly develop and manufacture a COVID-19 Point of Care antibody test as part of...
Calls are ordered by closing date. The soonest call to close is listed first. IMI2 – Call 21 (Development of therapeutics and diagnostics combatting coronavirus infections) Closing Date: 31st March Funding type: Grant Scheme Value: £45m Application Restrictions: Applications from companies welcomed Description: Considering that this is a newly-identified virus, the scope of this topic remains broad and must address at least one of the...
The 2017 Life Sciences Strategy for Scotland laid out a ‘2025 Vision’ to grow the industrial turnover of the life sciences sector to £8 billion by focussing on 4 strategic themes. The Sustainable Production Group (SPG) is one of the working groups formed with the Life Sciences Scotland Industry Leadership Group and members of the broader life sciences community to plan and coordinate the delivery...
Almost fifty years on from the closure of the Cupar Sugar Beet factory, a Rural Innovation Support Service (RISS) group aims to look into the feasibility and steps required to re-establish the crop and its processing in eastern Scotland. The 2020 driver is to contribute to climate change mitigation, rather than sugar for human consumption, and the decarbonisation of industry to meet Scotland’s greenhouse gas reduction...
AorTech International plc (AIM: AOR.L), the licensor of the world’s leading long-term implantable biostable polymer (Elast-EonTM) and developer of medical devices utilising the key properties of Elast-EonTM, is pleased to update on the progress of the design for manufacture process for its polymeric heart valve. In its interim results announced on 29 November 2019, the Company stated that it was continuing to make good progress on both...